CTCs-derived xenograft development in a triple negative breast cancer case

Area of Science:

• Oncology
• Cancer Biology
• Translational Research

Background:

• Triple-negative breast cancer (TNBC) presents significant clinical challenges due to high metastatic potential and lack of targeted therapies.
• Patient-derived xenografts (PDXs), particularly those derived from circulating tumor cells (CTCs), are valuable preclinical models for studying cancer biology and identifying therapeutic targets.

Purpose of the Study:

• To establish and characterize a novel CDX model from a TNBC patient.
• To elucidate the underlying molecular mechanisms driving TNBC tumor biology.
• To identify and validate potential biomarkers for TNBC prognosis and therapeutic targeting.

Main Methods:

• Development and characterization of a CDX model from a TNBC patient's circulating tumor cells.
• Analysis of WNT signaling pathways within the CDX model.
• Identification and validation of potential CTC markers in a cohort of TNBC patients.
• Assessment of MELK expression levels and correlation with patient survival data.

Main Results:

• Successful establishment of a CDX model from a TNBC patient, demonstrating tumorigenicity of CTCs.
• WNT signaling identified as a predominant mechanism in the tumor biology of this TNBC CDX model.
• Potential CTC markers were identified and subsequently validated in TNBC patients.
• High MELK expression levels were significantly associated with poorer survival rates in the studied TNBC cohort.

Conclusions:

• CTCs from triple-negative breast cancer are tumorigenic and can be utilized to establish functional xenograft models.
• CDX models serve as powerful tools for gaining insights into TNBC biology and identifying therapeutic targets.
• WNT signaling and MELK expression represent important areas for further investigation in TNBC treatment and prognosis.